Systematic Review and Meta-Analysis: Circulating miRNAs for Diagnosis of Hepatocellular Carcinoma

Journal of Cellular Physiology

Volumn 231, Issue 2, 2016, Pages 328-335

  Huang, Jing Tao ^a   Liu, Song Mei ^a   Ma, Haiqing ^b   Yang, Ying ^a   Zhang, Xuan ^c   Sun, Huanhuan ^b   Zhang, Xiaoyan ^c   Xu, Jianqing ^c   Wang, Jin ^c,d  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b THE FIFTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c SHANGHAI PUBLIC HEALTH CLINICAL CENTER   (China)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; ALPHA FETOPROTEIN; BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; MICRORNA; MICRORNA 122; MICRORNA 21; MIRN122 MICRORNA, HUMAN; MIRN21 MICRORNA, HUMAN; RNA; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CNKI DATABASE; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; EMBASE; HEPATITIS B; HEPATITIS C; HUMAN; INFORMATION RETRIEVAL; LABORATORY TEST; LIVER CELL CARCINOMA; MEDLINE; META ANALYSIS (TOPIC); NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW (TOPIC); BLOOD; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; GENETICS; LIVER NEOPLASMS; META ANALYSIS; PREDICTIVE VALUE;

BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; EARLY DIAGNOSIS; HUMANS; LIVER NEOPLASMS; MICRORNAS; PREDICTIVE VALUE OF TESTS; RNA, NEOPLASM;

EID: 84945449285     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25135     Document Type: Article

References (56)

1. Abdalla MA, Haj-Ahmad Y. 2012. Promising Candidate Urinary MicroRNA Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients. J Cancer 3:19-31.
2. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H. 2008. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27:2128-2136.
3. Bartel DP. 2009. MicroRNAs: Target recognition and regulatory functions. Cell 136:215-233.
4. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. 2008. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 48:137-145.
5. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. 2003. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625-1638.
6. Chen L, Chu F, Cao Y, Shao J, Wang F. 2015. Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma. Tumour biology doi: 10.1007/s13277-015- 3430-2
7. Collier J, Sherman M. 1998. Screening for hepatocellular carcinoma. Hepatology 27:273-278.
8. Deeks JJ, Macaskill P, Irwig L. 2005. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 58:882-893.
9. El-Serag HB. 2011. Hepatocellular carcinoma. N Engl J Med 365:1118-1127.
10. El-Serag HB, Tran T, Everhart JE. 2004. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126:460-468.
11. Forner A, Llovet JM, Bruix J. 2012. Hepatocellular carcinoma. Lancet 379:1245-1255.
12. Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A. 2008. MiR-122, a paradigm for the role of microRNAs in the liver. J Hepatol 48:648-656.
13. Hu J, Xu Y, Hao J, Wang S, Li C, Meng S. 2012. MiR-122 in hepatic function and liver diseases. Protein Cell 3:364-371.
14. Huang JT, Liu YJ, Wang J, Xu ZG, Yang Y, Shen F, Liu XH, Zhou X, Liu SM. 2015. Next generation digital PCR measurement of hepatitis B virus copy number in formalin-fixed paraffin-embedded hepatocellular carcinoma tissue. Clin Chem 61:290-296.
15. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW. 2009. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361:1437-1447.
16. Jiang L, Li X, Cheng Q, Zhang BH. 2015. Plasma microRNA might as a potential biomarker for hepatocellular carcinoma and chronic liver disease screening. Tumour Biol.
17. Kapitanov T, Neumann UP, Schmeding M. 2015. Hepatocellular Carcinoma in Liver Cirrhosis: Surgical Resection versus Transarterial Chemoembolization-A Meta-Analysis. Gastroenterol Res Pract 2015:696120.
18. Korzeniewski N, Tosev G, Pahernik S, Hadaschik B, Hohenfellner M, Duensing S. 2015. Identification of cell-free microRNAs in the urine of patients with prostate cancer. Urol Oncol 33:e17-e22.
19. Li F, Ma N, Zhao R, Wu G, Zhang Y, Qiao Y, Han D, Xu Y, Xiang Y, Yan B, Jin J, Lv G, Wang L, Xu C, Gao X, Luo S. 2014a. Overexpression of miR-483-5p/3p cooperate to inhibit mouse liver fibrosis by suppressing the TGF-β stimulated HSCs in transgenic mice. J Cell Mol Med 18:966-974.
20. Li L, Guo Z, Wang J, Mao Y, Gao Q. 2012. Serum miR-18a: A potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig Dis Sci 57:2910-2916.
21. Li T, Yin J, Yuan L, Wang S, Yang L, Du X, Lu J. 2014b. Downregulation of microRNA-139 is associated with hepatocellular carcinoma risk and short-term survival. Oncol Rep 31:1699-1706.
22. Liu AM, Yao TJ, Wang W, Wong KF, Lee NP, Fan ST, Poon RT, Gao C, Luk JM. 2012. Circulating miR -15b and miR -130b in serum as potential markers for detecting hepatocellular carcino ma: A retrospective cohort study. BMJ Open 2:e000825.
23. Liu CZ, Yu J, Yu SN, Lavker RM, Cai L, Liu W, Yang KG, He XD, Chen SS. 2010. MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma. J Hepatol 53:98-107.
24. Llovet JM, Schwartz M, Mazzaferro V. 2005. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 25:181-200.
25. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. 2005. MicroRNA expression profiles classify human cancers. Nature 435:834-838.
26. Luo J, Chen M, Huang H, Yuan T, Zhang M, Zhang K, Deng S. 2013. Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma. Onco Targets Ther 6:577-583.
27. Ma N, Li F, Li D, Hui Y, Wang X, Qiao Y, Zhang Y, Xiang Y, Zhou J, Zhou L, Zheng X, Gao X. 2012. Igf2-derived intronic miR-483 promotes mouse hepatocellular carcinoma cell proliferation. Mol Cell Biochem 361:337-343.
28. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD, Patel T. 2006. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130:2113-2129.
29. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. 2007. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133:647-658.
30. Nakao K, Miyaaki H, Ichikawa T. 2014. Antitumor function of microRNA-122 against hepatocellular carcinoma. J Gastroenterol 49:589-593.
31. Qi J, Wang J, Katayama H, Sen S, Liu SM. 2013. Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma 60:135-142.
32. Qi JH, Wang J, Chen JY, Shen F, Huang JT, Sen S, Zhou X, Liu SM. 2014. High-resolution melting analysis reveals genetic polymorphisms in MicroRNAs confer hepatocellular carcinoma risk in Chinese patients. Bmc Cancer 14:643.
33. Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF. 2011. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS ONE 6:e28486.
34. Qiu D, Katanoda K, Marugame T, Sobue T. 2009. A Joinpoint regression analysis of long-term trends in cancer mortality in Japan (1958-2004). Int J Cancer J Int du Cancer 124:443-448.
35. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. 2011. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 45:355-360.
36. Shen J, Wang A, Wang Q, Gurvich I, Siegel AB, Remotti H, Santella RM. 2013. Exploration of genome-wide circulating microRNA in hepatocellular carcino ma: MiR -483-5p as a potential biomarker. Cancer Epidemiol Biomarkers Prev 22:2364-2373.
37. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. 2007. MiR-21-mediated tumor growth. Oncogene 26:2799-2803.
38. Sidhu K, Kapoor NR, Pandey V, Kumar V. 2015. The "Macro" World of microRNAs in Hepatocellular Carcinoma. Frontiers oncol 5:68.
39. Tan AC, Fan JB, Karikari C, Bibikova M, Garcia EW, Zhou L, Barker D, Serre D, Feldmann G, Hruban RH, Klein AP, Goggins M, Couch FJ, Hudson TJ, Winslow RL, Maitra A, Chakravarti A. 2008. Allele-specific expression in the germline of patients with familial pancreatic cancer: An unbiased approach to cancer gene discovery. Cancer Biol Ther 7:135-144.
40. Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X, Zhou X, Gan J. 2014. A Serum MicroRNA Panel as Potential Biomarkers for Hepatocellular Carcinoma Related with Hepatitis B Virus. PLoS ONE 9:e107986.
41. Tian T, Wang JQ, Zhou X. 2015. A review: microRNA detection methods. Org Biomol Chem 13:2226-2238.
42. Tian T, Xiao H, Zhang X, Peng S, Zhang X, Guo S, Wang S, Liu S, Zhou X, Meyers C, Zhou X. 2013. Simultaneously sensitive detection of multiple miRNAs based on a strand displacement amplification. Chem commun 49:75-77.
43. Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S, Tanemura M, Tomokuni A, Takemasa I, Umeshita K, Kanto T, Doki Y, Mori M. 2012. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 56:167-175.
44. Trepo C, Chan HL, Lok A. 2014. Hepatitis B virus infection. Lancet 384:2053-2063.
45. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, Huang Y, Chen HC, Lee CH, Tsai TF, Hsu MT, Wu JC, Huang HD, Shiao MS, Hsiao M, Tsou AP. 2012. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 122:2884-2897.
46. Walter SD. 2002. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med 21:1237-1256.
47. Wang J, Zhang KY, Liu SM, Sen S. 2014a. Tumor-associated circulating microRNAs as biomarkers of cancer. Molecules 19:1912-1938.
48. Wang J, Chen J, Sen S. 2015. MicroRNA as Biomarkers and Diagnostics. J Cell Physiol doi: 10.1002/jcp.25056.
49. Wang S, Fu B, Wang J, Long Y, Zhang X, Peng S, Guo P, Tian T, Zhou X. 2014b. Novel amplex red oxidases based on noncanonical DNA structures: Property studies and applications in microRNA detection. Anal chem 86:2925-2930.
50. Wen Y, Han J, Chen J, Dong J, Xia Y, Liu J, Jiang Y, Dai J, Lu J, Jin G, Han J, Wei Q, Shen H, Sun B, Hu Z. 2015. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. Int J Cancer J Int du cancer 137:1679-1690.
51. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM. Grou p Q-. 2011. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Internal Med 155:529-536.
52. Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, Huang L, Li H, Tan W, Wang C, Lin D. 2011. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 50:136-142.
53. Zeisel MB, Pfeffer S, Baumert TF. 2013. MiR-122 acts as a tumor suppressor in hepatocarcinogenesis in vivo. J Hepatol 58:821-823.
54. Zhang ZQ, Meng H, Wang N, Liang LN, Liu LN, Lu SM, Luan Y. 2014. Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma. Diagnostic pathol 9:135.
55. Zheng H, Zhang L, Zhao Y, Yang D, Song F, Wen Y, Hao Q, Hu Z, Zhang W, Chen K. 2013a. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS ONE 8:e77853. doi: 10.1371/journal.pone.0077853
56. Zheng JJ, Yu FJ, Dong PH, Bai YH, Chen BC. 2013b. [Expression of miRNA-29b and its clinical significances in primary hepatic carcinoma]. Zhonghua Yi Xue Za Zhi 93:888-891.